SEARCH

SEARCH BY CITATION

References

  • 1
    National Institutes of Health Consensus Development Conference. Management of Hepatitis C. Hepatology 1997; 26: 1S156S (suppl 1).
  • 2
    Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556562.
  • 3
    Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777782.
  • 4
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958965.
  • 5
    Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natura history, treatment and prevention of hepatitis C. Ann Intern Med 2000; 132: 296305.